Abstract

Background:Several oral therapies are approved for use in combination with metformin; however, they are not always effective and are associated with side effects. Vildagliptin and metformin have independent glucose-lowering properties and demonstrated great glycemic control and tolerance in patients with T2DM.Aim: To evaluate the efficacy of vildagliptin-metformin combination treatment in type 2 diabetes mellitus patients.Material and Methods:A total of 35 patients with T2DM were given Vildagliptin(50mg)+ metformin(500mg) twice daily half an hour before meals was advised. Primary efficacy outcome was measured in terms of reduction in HbA1c levels from baseline to 12th week and reduction in FBS/PPBS levels from baseline to 6th and 12th week.Results:The mean fasting blood sugar levels at baseline (0 weeks) was174.03 ±19.19 mg/dl and the change in percentage at 12 weeks was -39.33%. The mean post prandial sugar levels at baseline (0 weeks) was 277.94 ±28.41 mg/dl and the change in percentage at 12 weeks was -43.88%. The mean HbA1c levels at baseline (0 weeks) was 8.99 ±0.37 and at 12 weeks it was 6.42±0.42 with change of -27.86%.Conclusion:Vildagliptin in combination with metformin also had good safety with low risk of hypoglycaemia and weight gain.

Authors and Affiliations